Carboplatin is a platinum-based drug indicated in adults, among other approved uses. It is available as injection for intravenous use. MedsAcross supplies Carboplatin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
KYXATA is a platinum-based drug indicated in adults: As part of a combination regimen, for the initial treatment of advanced ovarian carcinoma. As a single-agent for the treatment of ovarian carcinoma recurrent after prior chemotherapy.
Source: US FDA prescribing information
Carboplatin is a platinum-based drug that binds to DNA and forms DNA cross-links. These crosslinks inhibit DNA replication and transcription and trigger cytotoxic processes that lead to cell death.
Source: US FDA prescribing information
Initial Treatment of Advanced Ovarian Carcinoma: KYXATA 300 mg/m 2 -OR- AUC of 4 mg/mL∙min to 6 mg/mL∙min intravenously in combination with cyclophosphamide on Day 1 every 4 weeks for each cycle. Administer up to six cycles or until disease progression or unacceptable toxicity occurs. Recurrent Advanced Ovarian Carcinoma as a Single Agent: KYXATA 360 mg/m 2 - OR - AUC of 4 mg/mL∙min to 6 mg/mL∙min intravenously on Day 1 every 4 weeks for each cycle until disease progression or unacceptable toxicity occurs. Avoid contact of carboplatin with aluminum parts.
Source: US FDA prescribing information
None. None.
Source: US FDA prescribing information
Boxed warning (hypersensitivity reactions, including anaphylaxis): Serious and life-threatening hypersensitivity reactions, including anaphylaxis, can occur with KYXATA within minutes of administration during any cycle. Immediately discontinue KYXATA for severe hypersensitivity reactions and administer appropriate treatment for management of the hypersensitivity reaction. Myelosuppression: Myelosuppression (leukopenia, neutropenia, and thrombocytopenia) can cause severe or fatal infections or hemorrhage. Monitor complete blood counts prior to each treatment cycle, and as clinically indicated. If myelosuppression occurs, modify KYXATA dosage. Nausea and Vomiting: Administer pre-treatment and post-treatment antiemetics as clinically indicated. Peripheral Neuropathy: Peripheral neuropathy, including paresthesia, can occur in patients treated with KYXATA.
Source: US FDA prescribing information
The following clinically significant adverse reactions are described elsewhere in the labeling: Hypersensitivity Myelosuppression Nausea and Vomiting Peripheral Neuropathy Most common adverse reactions, including laboratory abnormalities, in patients with advanced ovarian cancer who received KYXATA in combination with cyclophosphamide (≥30%) are leukopenia, neutropenia, nausea and vomiting, anemia, thrombocytopenia, hypomagnesemia, other gastrointestinal adverse reactions, alopecia, asthenia, and pain. Most common adverse reactions, including laboratory abnormalities, in patients with recurrent ovarian cancer who received KYXATA as a single agent (≥30%) are nausea and vomiting, anemia, neutropenia, thrombocytopenia, hyponatremia, hypomagnesemia, hyperphosphatasemia, and hypocalcemia.
Source: US FDA prescribing information
Aminoglycosides: Avoid concomitant use with aminoglycosides. Use with Aminoglycosides Avoid concomitant use of aminoglycosides with KYXATA. Concomitant use of KYXATA with aminoglycosides increased renal toxicity and ototoxicity.
Source: US FDA prescribing information
Store at 20°C to 25°C (68°F to 77°F), excursions permitted from 15°C to 30°C (59°F to 86°F). Protect from light.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
6 presentations of Carboplatin, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Carboplatin 600 mg/60 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Carboplatin 450 mg/45 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Carboplatin 150 mg/15 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Carboplatin 50 mg/5 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Kyxata 500 mg/50 mL injectionIntravenous | Avyxa Pharma | US FDA | Available on request |
| Kyxata 80 mg/8 mL injectionIntravenous | Avyxa Pharma | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 3 March 1989 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Carboplatin in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 6 presentations of Carboplatin and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Carboplatin, including Kyxata.
Yes. The US FDA first approved Carboplatin on 3 March 1989, according to Drugs@FDA.
No listed presentation of Carboplatin is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Carboplatin is classified under ATC code L01XA02 (Carboplatin).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.